apremilast
PolandDrugs containing this active substance
-
The medicine is used in adults with active psoriatic arthritis, chronic plaque psoriasis (moderate to severe), and Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 10 mg or 20 mg or 30 mg ATC: L04AA32
Manufacturer: Adalvo Ltd. Pharmadox Healthcare Limited
-
The medicine is used in adults with active psoriatic arthritis, chronic plaque psoriasis (moderate to severe), and Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 30 mg ATC: L04AA32
Manufacturer: Adalvo Ltd. Pharmadox Healthcare Limited
-
The medicine is intended for adult patients with active psoriatic arthritis, moderate to severe chronic plaque psoriasis, and Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 10 mg or 20 mg or 30 mg ATC: L04AA32
Manufacturer: Farmaprojects S.A.U.
-
The medicine is used in adult patients with active psoriatic arthritis, moderate to severe chronic plaque psoriasis, and for the treatment of oral ulcers in patients with Behçet's disease.
Form: tablets, film-coated
Active substance Dosage apremilast 30 mg ATC: L04AA32
Manufacturer: Farmaprojects S.A.U.
-
This medicine is used in adults to treat active psoriatic arthritis, moderate to severe chronic plaque psoriasis, and Behçet's disease (to treat oral ulcers). In children and adolescents (from 6 years of age, weighing at least 20 kg), it is used to treat plaque psoriasis.
Form: tablets, film-coated
Active substance Dosage apremilast 10 mg or 20 mg or 30 mg ATC: L04AA32
Manufacturer: Krka, d.d., Novo mesto
-
The medicine is used in adults for the treatment of active psoriatic arthritis, moderate to severe chronic plaque psoriasis, and Behçet's disease (to treat oral ulcers). In children and adolescents (from 6 years of age weighing at least 20 kg), it is used for the treatment of plaque psoriasis.
Form: tablets, film-coated
Active substance Dosage apremilast 30 mg ATC: L04AA32
Manufacturer: Krka, d.d., Novo mesto
-
It is used in adults for the treatment of active psoriatic arthritis, moderate to severe chronic plaque psoriasis, and Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 10 mg or 20 mg or 30 mg ATC: L04AA32
Manufacturer: Adalvo Ltd. Pharmadox Healthcare Limited
-
The medicine is used in adult patients with active psoriatic arthritis, moderate to severe chronic plaque psoriasis, and in Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 30 mg ATC: L04AA32
Manufacturer: Adalvo Ltd. Pharmadox Healthcare Limited
-
The medicine is used in adult patients with active psoriatic arthritis, chronic plaque psoriasis (moderate to severe), and Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 10 mg or 20 mg or 30 mg ATC: L04AA32
Manufacturer: Polpharma Pharmaceutical Works S.A.
-
It is used in adults with active psoriatic arthritis, chronic plaque psoriasis (moderate to severe), and in Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 30 mg ATC: L04AA32
Manufacturer: Polpharma Pharmaceutical Works S.A.
-
The medicine is used in adults with active psoriatic arthritis, chronic plaque psoriasis (moderate to severe), and in Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 30 mg ATC: L04AA32
Manufacturer: Lek Pharmaceuticals d.d. Salutas Pharma GmbH
-
The medicine is used in adults suffering from active psoriatic arthritis, moderate to severe chronic plaque psoriasis, and Behçet's disease (for the treatment of oral ulcers).
Form: tablets, film-coated
Active substance Dosage apremilast 10 mg or 20 mg or 30 mg ATC: L04AA32
Manufacturer: Lek Pharmaceuticals d.d. Salutas Pharma GmbH